HighlightsOrder placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial releaseInitial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company websiteEach patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news releaseVancouver ...